We are live on ! Find out more
BOLD icon

Audentes Therapeutics
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

58 hedge funds and large institutions have $272M invested in Audentes Therapeutics in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

722% more capital inflows, than outflows

Capital inflows: $24.1M | Capital outflows: $2.93M

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

2% more funds holding

Funds holding: 57 → 58 (+1)

1.57% more ownership

Funds ownership: 71.34% → 72.91% (+1.6%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
58
Holders Change
+1
Holders Change %
+1.75%
% of All Funds
1.44%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
19
Reduced
15
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BOLD Hedge Fund Activity: Q1 2017 in Review

58 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics (BOLD) for Q1 2017, worth a combined $272M — down 3.8% from $283M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new BOLD positions and 2 closed out — a net gain of 7 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $13.9M. The largest seller was AllianceBernstein, cutting an estimated $748K.

  • 58 institutional investors held Audentes Therapeutics (BOLD) as of Q1 2017, up from 57 in Q4 2016.
  • Funds reported $272M of Audentes Therapeutics stock for Q1 2017, down 3.8% quarter-over-quarter.
  • 9 funds opened new Audentes Therapeutics positions in Q1 2017 and 2 closed out, a net change of +7 holders.
  • The largest Audentes Therapeutics buyer in Q1 2017 was BlackRock, an estimated $13.9M added.
  • The largest Audentes Therapeutics seller in Q1 2017 was AllianceBernstein, an estimated $748K sold.

Based on aggregated 13F filings for Q1 2017.